Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases).


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
Nov 2024
Historique:
received: 09 11 2023
revised: 14 02 2024
accepted: 05 03 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: ppublish

Résumé

An uncontrolled activity of neutrophil serine proteases (NSPs) contributes to inflammatory diseases. Cathepsin C (CatC) is known to activate NSPs during neutrophilic differentiation and represents a promising pharmacological target in NSP-mediated diseases. In humans, Papillon-Lefèvre syndrome (PLS) patients have mutations in theirCTSC gene, resulting in the complete absence of CatC activity. Despite this, low residual NSP activities are detected in PLS neutrophils (<10% vs healthy individuals), suggesting the involvement of CatC-independent proteolytic pathway(s) in the activation of proNSPs. This prompted us to characterize CatC-independent NSP activation pathways by blocking proCatC maturation. In this study, we show that inhibition of intracellular CatS almost completely blocked CatC maturation in human promyeloid HL-60 cells. Despite this, NSP activation was not significantly reduced, confirming the presence of a CatC-independent activation pathway involving a CatC-like protease that we termed NSPs-AAP-1. Similarly, when human CD34

Identifiants

pubmed: 39455238
pii: S0006-2952(24)00097-2
doi: 10.1016/j.bcp.2024.116114
pii:
doi:

Substances chimiques

Cathepsins EC 3.4.-
cathepsin S EC 3.4.22.27
Cathepsin C EC 3.4.14.1
Serine Proteases EC 3.4.-
Serine Proteinase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116114

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Brice Korkmaz has been paid for the time spent as a committee member for advisory boards (Brensocatib Advisory Board (BRAB), INSMED, USA), other forms of consulting (Boehringer Ingelheim (Germany), Neuprozyme Therapeutics Aps (Denmark), Santhera Pharmaceuticals (Switzerland), Chiesi (Italy), Gerson Lehrman Group (GLG) (USA), Slingshot Insights expert network (USA)), symposium organisation (INSMED, Boehringer Ingelheim, Chiesi) and travel support, lectures or presentations, outside the submitted work. Other authors declare no competing financial interests.

Auteurs

Roxane Domain (R)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Seda Seren (S)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Uwe Jerke (U)

Experimental and Clinical Research Center, Charité und Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Berlin, Germany.

Manousos Makridakis (M)

Biotechnology Division, Biomedical Research Foundation, Academy of Athens, Athens, Greece.

Kuan-Ju Chen (KJ)

Research Department, Insmed Incorporated, Bridgewater, NJ, USA.

Jérôme Zoidakis (J)

Biotechnology Division, Biomedical Research Foundation, Academy of Athens, Athens, Greece.

Moez Rhimi (M)

INRAE UMR-1319, Microbiota Interaction with Human and Animal Team (MIHA), Micalis Institute, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.

Xian Zhang (X)

School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, China.

Tillia Bonvent (T)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Cécile Croix (C)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Loïc Gonzalez (L)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Dedong Li (D)

Research Department, Insmed Incorporated, Bridgewater, NJ, USA.

Jessica Basso (J)

Research Department, Insmed Incorporated, Bridgewater, NJ, USA.

Christophe Paget (C)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Marie-Claude Viaud-Massuard (MC)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Gilles Lalmanach (G)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France.

Guo-Ping Shi (GP)

Department of Medicine, Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Ali Aghdassi (A)

Department of Medicine A - Gastroenterology, Nephrology, Endocrinology and Rheumatology, University Medicine Greifswald, Greifswald, Germany.

Antonia Vlahou (A)

Biotechnology Division, Biomedical Research Foundation, Academy of Athens, Athens, Greece.

Patrick P McDonald (PP)

Research Department, Insmed Incorporated, Bridgewater, NJ, USA.

Isabelle Couillin (I)

CNRS UMR-7355, Experimental and Molecular Immunology and Neurogenetics, Université d'Orléans, Orleans, France.

Rich Williams (R)

The Patrick G Johnston Center for Cancer Research, Queen's University, Belfast, UK.

Ralph Kettritz (R)

Experimental and Clinical Research Center, Charité und Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Berlin, Germany; Nephrology and Intensive Care Medicine, Charité-Universitätsmedizin, Berlin, Germany.

Brice Korkmaz (B)

INSERM UMR-1100, Research Center for Respiratory Diseases, Tours, France; Université de Tours, Tours, France. Electronic address: brice.korkmaz@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH